BioSpace News Archive

IO Biotech announced today that the first patient has been dosed in its Phase 2 trial (NCT05280314) studying treatment with IO102-IO103 in combination with Merck’s anti-PD-1 therapy KEYTRUDA.

TransThera today announces the first patient has been dosed in the US for the Phase 3 trial FIRST-308 of tinengotinib (TT-00420).

NS Pharma, Inc. has granted orphan drug designation for NS-089/NCNP-02, which is being developed for the treatment of Duchenne muscular dystrophy (Duchenne).

Pluristyx, a leading provider of tools, technologies and services for the development of cell therapies, has today announced the closing of a major fundraising round led by BroadOak Capital Partners.

Pressure BioSciences, Inc. today announced the publication of a powerful visionary article in the respected industry trade magazine “Food Technology” published by the Institute of Food Technologists (“IFT”).

Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, today announces the signing of a binding Head of Terms (HoT) agreement for the commercialization of DONESTA® in Israel with Rafa Laboratories LTD, an Israeli pharmaceutical company.

Hyloris Pharmaceuticals SA, a specialty biopharma company committed to addressing unmet medical needs through reinventing existing medications, announces that it has entered into a partnership with AFT Pharmaceuticals to co-develop HY-090, a novel locally-acting product candidate for the treatment of Burning Mouth Syndrome.

Alcresta Therapeutics, Inc., a leading commercial-stage company focused on developing and commercializing novel enzyme-based products, today announced 510(k) clearance of its next-generation RELiZORB® (iMMOBILIZED LIPASE) cartridge by the Center for Devices and Radiological Health (CDRH) of the U.S. Food and Drug Administration (FDA).

Biodexa Pharmaceuticals PLC announced the closing of an underwritten public offering of units for gross proceeds of approximately $6.0 million, which includes the full exercise of the underwriter’s over-allotment option to purchase additional shares and warrants, prior to deducting underwriting discounts and commissions and offering expenses payable by Biodexa.

Galecto, Inc., a clinical stage biotechnology company focused on the development of novel treatments for fibrosis and cancer, announced positive topline results from a Phase 2a trial of GB2064 for the treatment of myelofibrosis.